Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 15, 2022 10:13am
242 Views
Post# 35173039

RE:Completely unprepared for this outcome

RE:Completely unprepared for this outcomeWe get your frustration but daily venting on this board won't help. If you want a dose of positivity, you could also say that as they were seeing results come in from the basket trial they thought that over a trial of 50 or so people they would see the required minimum of 2 with response or were at least getting close, but got stuck at stable or went off treatment. They were clearly expecting more given the indications like hiring,etc. So there must have been something in there to see, but in the end data was off-pace to see that so hit the pause, not the stop button.

As they've said, all involved were tasked to rethink the regimen to push activity harder up front like some other drugs do. They'll have to discuss this thinking and what the data has informed them around. I'm not at all dismissing the fact there was minimal de-risking, but sort of like othesr up here said earlier, there may be parts of the proof of concept they can understand better around the peptide and mechanisms or sort1 as a target. They'll have to have some level of understanding and discussion to get the new protocol approved by FDA and then they can discuss it more widely. So at some point you'll hear those obesrvations they saw as it went from 1a to 1b and then hit reset.

Trogarzon wrote: Not being prepared for such an outcome comes to mind. After the crazy hiring binge and analyst pow wow.  It’s being caught with your pants down really.  Now they have to reverse engineer and have not prepare for this outcome obviously.  While we wait for them to recover their balance from the jab they’ve been served we are trading at level I would never have imagined possible before... never... it’s beyond bad and they should be all fired immediately for this fact.  Not only the fact that they have to pause, the whole way they stubbornly achieved nothing for the last 5 years. The board, the management, everyone over there out... call Remax now for Christ sake.


<< Previous
Bullboard Posts
Next >>